SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
NCT ID: NCT00304148
Last Updated: 2025-11-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Total Enrollment
5499 participants
Study Classification
OBSERVATIONAL
Study Start Date
2003-07-31
Study Completion Date
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Chronic kidney disease (CKD) is a silent epidemic affecting more than 37 million Americans. The burden of morbidity and mortality associated with CKD derives from its frequent progression to end-stage kidney disease (ESKD) and the disproportionate risk of cardiovascular disease (CVD) and associated complications. CKD is strongly and independently associated with CVD, even after adjustment for traditional CVD risk factors. This led to the hypothesis that other risk factors augment the rate of CVD in the setting of CKD. Hence, many patients with progressive renal disease succumb to fatal CVD events before they need renal replacement therapy.
The National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) established the Chronic Renal Insufficiency Cohort (CRIC) Study in 2001 with the initial goal of elucidating the relationship between CKD and CVD. Since its inception, the CRIC Study has recruited and followed a racially and ethnically diverse cohort of over 5,000 participants with reduced kidney function from 13 clinical recruitment sites across the US. The original aim of CRIC was to establish a clinical research laboratory designed to (a) identify novel predictors of CKD progression, and (b) characterize the manifestations of CVD and identify its risk factors among individuals with CKD. The CRIC Study has examined a broad set of etiological factors (clinical, behavioral, and biomarker-associated) potentially responsible for both progressive CKD and CKD-related morbidities, especially those early in the course of CKD. Characterizing relationships between these risk factors and outcomes should facilitate identification of high-risk subgroups with CKD and guide enrollment into preventive treatment trials and application of preventive therapies. Over time, the scientific focus and the CRIC investigator network have broadened extensively through a highly successful ancillary studies program that has included more than 100 projects, most of which have been funded through federal grants. To date, the CRIC Study's investigative activities have resulted in over 300 published scientific papers with many additional manuscripts in development.
The National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) established the Chronic Renal Insufficiency Cohort (CRIC) Study in 2001 with the initial goal of elucidating the relationship between CKD and CVD. Since its inception, the CRIC Study has recruited and followed a racially and ethnically diverse cohort of over 5,000 participants with reduced kidney function from 13 clinical recruitment sites across the US. The original aim of CRIC was to establish a clinical research laboratory designed to (a) identify novel predictors of CKD progression, and (b) characterize the manifestations of CVD and identify its risk factors among individuals with CKD. The CRIC Study has examined a broad set of etiological factors (clinical, behavioral, and biomarker-associated) potentially responsible for both progressive CKD and CKD-related morbidities, especially those early in the course of CKD. Characterizing relationships between these risk factors and outcomes should facilitate identification of high-risk subgroups with CKD and guide enrollment into preventive treatment trials and application of preventive therapies. Over time, the scientific focus and the CRIC investigator network have broadened extensively through a highly successful ancillary studies program that has included more than 100 projects, most of which have been funded through federal grants. To date, the CRIC Study's investigative activities have resulted in over 300 published scientific papers with many additional manuscripts in development.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Visits and Participant Contact
During its 5th and final phase, the 7 Clinical Centers comprised of 12 sites will extend participant follow-up for participants who have not reached ESKD before the inception of Phase 5 by conducting 2 study visits. For all participants, Visit 1 is conducted in person at the study site. Visit 2 can be conducted in person or by telephone. For participants who enrolled in one or more Phase 4 subprotocols, Visit 2 requires a blood draw for a creatinine measurement. The blood draw can be performed at the study site, at a commercial laboratory, or at the participant's home. The principal focus for these study visits is to ascertain kidney and clinical CVD outcomes, both of which are of particular importance for the participants who enrolled in the three Phase 4 subprotocols. Participants may be contacted at other times during the year to answer additional questions or to join ancillary studies. Participants who are known by the study team to have ESKD will not have any in-person visits or scheduled telephone calls.
Phase 5 Visit 1
Participants without ESKD will complete one initial visit through the end of 2024 (Visit 1) and one follow up visit during the following year (Visit 2). Data collection has been streamlined in accordance with the Phase 5 objectives . At the in-person visit, informed consent will be obtained for continued participation in the CRIC Study. Blood pressure, weight, and medical history data will be obtained using standardized equipment and protocols established previously in the CRIC Study. Blood and urine samples will be collected for serum creatinine, serum cystatin C, and urine protein/creatinine, the key indicators of kidney outcomes. Serum creatinine will be measured locally using CLIA-approved laboratories, and serum cystatin C and urine protein/creatinine will be measured at the CRIC Central Laboratory (CCL) at the University of Pennsylvania. As has been done in earlier phases, the results of the serum creatinine measurement will be provided to participants. Serum and urine remaining after the centralized measurements will be stored at the CCL during the Phase 5 award period for potential analyses in the future. For participants who are unable to come to the Clinical Center for an in-person visit, informed consent and the medical history and hospitalization data will be obtained by telephone. Participants should be encouraged to get blood drawn at a laboratory or at their home if they are not able to come to the Clinical Center.
Phase 5 Visit 2
The follow-up visit for participants without ESKD can take place by telephone or in person. During the follow-up visit, medical history updates and hospitalization data will be collected.
The subset of participants who participated in any of the three Phase 4 subprotocols will be asked to have a second blood draw for creatinine measurement at or around the time of Visit 2. The creatinine measurement can be performed at the study site, at a commercial laboratory, or at the participant's home.
Follow-up of Participants who have Reached ESKD
Participants who have reached ESKD before the start of Phase 5 will not have in person visits but will be consented via a telephone visit for passive follow-up through linkages with the US Renal Data System, the National Death Index, and other national billing claims or other databases. These participants will also be asked to consent to sharing their contact information with the SDCC to facilitate potential future studies. Sharing of contact information is not required for participation in Phase 5. While participants who have reached ESKD will not undergo in-person visits as part of the core CRIC Phase 5 protocol, they may be invited to complete additional visits/activities for ancillary studies.
Close Out Activities
During the 3 years of the Clinical Center Phase 5 funding period, the Clinical Centers will hold local events to express appreciation to study participants for their contribution over many years and to provide them with an overview of major findings. The last 6 months of the Clinical Center funding period will focus on closeout activities including resolution of data queries, storage of study documents, and regulatory reporting and completion of outcome ascertainment.
During its 5th and final phase, the 7 Clinical Centers comprised of 12 sites will extend participant follow-up for participants who have not reached ESKD before the inception of Phase 5 by conducting 2 study visits. For all participants, Visit 1 is conducted in person at the study site. Visit 2 can be conducted in person or by telephone. For participants who enrolled in one or more Phase 4 subprotocols, Visit 2 requires a blood draw for a creatinine measurement. The blood draw can be performed at the study site, at a commercial laboratory, or at the participant's home. The principal focus for these study visits is to ascertain kidney and clinical CVD outcomes, both of which are of particular importance for the participants who enrolled in the three Phase 4 subprotocols. Participants may be contacted at other times during the year to answer additional questions or to join ancillary studies. Participants who are known by the study team to have ESKD will not have any in-person visits or scheduled telephone calls.
Phase 5 Visit 1
Participants without ESKD will complete one initial visit through the end of 2024 (Visit 1) and one follow up visit during the following year (Visit 2). Data collection has been streamlined in accordance with the Phase 5 objectives . At the in-person visit, informed consent will be obtained for continued participation in the CRIC Study. Blood pressure, weight, and medical history data will be obtained using standardized equipment and protocols established previously in the CRIC Study. Blood and urine samples will be collected for serum creatinine, serum cystatin C, and urine protein/creatinine, the key indicators of kidney outcomes. Serum creatinine will be measured locally using CLIA-approved laboratories, and serum cystatin C and urine protein/creatinine will be measured at the CRIC Central Laboratory (CCL) at the University of Pennsylvania. As has been done in earlier phases, the results of the serum creatinine measurement will be provided to participants. Serum and urine remaining after the centralized measurements will be stored at the CCL during the Phase 5 award period for potential analyses in the future. For participants who are unable to come to the Clinical Center for an in-person visit, informed consent and the medical history and hospitalization data will be obtained by telephone. Participants should be encouraged to get blood drawn at a laboratory or at their home if they are not able to come to the Clinical Center.
Phase 5 Visit 2
The follow-up visit for participants without ESKD can take place by telephone or in person. During the follow-up visit, medical history updates and hospitalization data will be collected.
The subset of participants who participated in any of the three Phase 4 subprotocols will be asked to have a second blood draw for creatinine measurement at or around the time of Visit 2. The creatinine measurement can be performed at the study site, at a commercial laboratory, or at the participant's home.
Follow-up of Participants who have Reached ESKD
Participants who have reached ESKD before the start of Phase 5 will not have in person visits but will be consented via a telephone visit for passive follow-up through linkages with the US Renal Data System, the National Death Index, and other national billing claims or other databases. These participants will also be asked to consent to sharing their contact information with the SDCC to facilitate potential future studies. Sharing of contact information is not required for participation in Phase 5. While participants who have reached ESKD will not undergo in-person visits as part of the core CRIC Phase 5 protocol, they may be invited to complete additional visits/activities for ancillary studies.
Close Out Activities
During the 3 years of the Clinical Center Phase 5 funding period, the Clinical Centers will hold local events to express appreciation to study participants for their contribution over many years and to provide them with an overview of major findings. The last 6 months of the Clinical Center funding period will focus on closeout activities including resolution of data queries, storage of study documents, and regulatory reporting and completion of outcome ascertainment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Renal Insufficiency, Chronic
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Renal Insufficiency Chronic
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CRIC Cohort
No interventions assigned to this group
CRIC Subcohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
During the screening visit a blood sample will be tested to indirectly check kidney function based on the serum creatinine level:
* Age Range: 21 - 79 years
* Estimated Glomerular Filtration Rate (GFR): 45 - 70 mL/min/1.73m²
* Proteinuria: varies dependent on eGRF
* Age Range: 21 - 79 years
* Estimated Glomerular Filtration Rate (GFR): 45 - 70 mL/min/1.73m²
* Proteinuria: varies dependent on eGRF
Exclusion Criteria
* Unable or unwilling to provide informed consent
* Previously received dialysis (peritoneal and/or hemodialysis) lasting more than one month
* Prior organ or bone marrow transplant
* Prior renal transplant
* Received immunosuppressive or other immunotherapy for primary renal disease or systemic vasculitis that affects the kidneys (i.e., anti-GCM, ANCA, SLE, IgA nephropathy, cryoglobulin, etc.) within the past six months before enrollment
* Received chemotherapy or alkylating agents for systemic cancer
* Known cirrhosis
* NYHA Class III or IV heart failure at baseline
* Previous diagnosis of multiple myeloma or renal carcinoma
* Previously diagnosed polycystic kidney disease
* Known HIV infection and/or AIDS
* Pregnant or breast-feeding women
* Currently participating in an interventional clinical trial (i.e., primarily trials of therapeutic agents that may have an effect on renal or cardiovascular outcomes).
* Institutionalized (e.g., prisoner, nursing home resident, skilled nursing facility resident)
* Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.
* Previously received dialysis (peritoneal and/or hemodialysis) lasting more than one month
* Prior organ or bone marrow transplant
* Prior renal transplant
* Received immunosuppressive or other immunotherapy for primary renal disease or systemic vasculitis that affects the kidneys (i.e., anti-GCM, ANCA, SLE, IgA nephropathy, cryoglobulin, etc.) within the past six months before enrollment
* Received chemotherapy or alkylating agents for systemic cancer
* Known cirrhosis
* NYHA Class III or IV heart failure at baseline
* Previous diagnosis of multiple myeloma or renal carcinoma
* Previously diagnosed polycystic kidney disease
* Known HIV infection and/or AIDS
* Pregnant or breast-feeding women
* Currently participating in an interventional clinical trial (i.e., primarily trials of therapeutic agents that may have an effect on renal or cardiovascular outcomes).
* Institutionalized (e.g., prisoner, nursing home resident, skilled nursing facility resident)
* Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.
Minimum Eligible Age
21 Years
Maximum Eligible Age
79 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Sponsor Role
collaborator
Johns Hopkins University
OTHER
Sponsor Role
collaborator
Case Western Reserve University
OTHER
Sponsor Role
collaborator
University of Michigan
OTHER
Sponsor Role
collaborator
University of Illinois at Chicago
OTHER
Sponsor Role
collaborator
Tulane University
OTHER
Sponsor Role
collaborator
Kaiser Permanente
OTHER
Sponsor Role
collaborator
University of Pennsylvania
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laura Dember, M.D.
Role: STUDY_DIRECTOR
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaiser Permanente of Northern California
Oakland, California, United States
Site Status
University of California
San Francisco, California, United States
Site Status
University of Illinois at Chicago
Chicago, Illinois, United States
Site Status
Tulane University Health Sciences Center
New Orleans, Louisiana, United States
Site Status
University of Maryland Medical System
Baltimore, Maryland, United States
Site Status
Johns Hopkins Medical Institutions
Baltimore, Maryland, United States
Site Status
University of Michigan Hospitals
Ann Arbor, Michigan, United States
Site Status
Wayne State - Harper University Hospital
Detroit, Michigan, United States
Site Status
University Hospitals of Cleveland
Cleveland, Ohio, United States
Site Status
Metrohealth Medical Center
Cleveland, Ohio, United States
Site Status
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Site Status
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S148-53. doi: 10.1097/01.asn.0000070149.78399.ce.
Reference Type
BACKGROUND
Wimmer NJ, Townsend RR, Joffe MM, Lash JP, Go AS; Chronic Renal Insufficiency Cohort Study Investigators. Correlation between pulse wave velocity and other measures of arterial stiffness in chronic kidney disease. Clin Nephrol. 2007 Sep;68(3):133-43.
Reference Type
BACKGROUND
Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, Levey AS. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007 Oct;18(10):2749-57. doi: 10.1681/ASN.2007020199. Epub 2007 Sep 12.
Reference Type
BACKGROUND
Xie D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, Greene T, Hsu CY, Kusek JW, Landis R, Lash J, Levey AS, O'Conner A, Ojo A, Rahman M, Townsend RR, Wang H, Feldman HI. A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1332-8. doi: 10.2215/CJN.05631207. Epub 2008 Jul 30.
Reference Type
RESULT
Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol. 2009 Aug;4(8):1302-11. doi: 10.2215/CJN.00070109. Epub 2009 Jun 18.
Reference Type
RESULT
DeLoach SS, Appel LJ, Chen J, Joffe MM, Gadegbeku CA, Mohler ER 3rd, Parsa A, Perumal K, Rafey MA, Steigerwalt SP, Teal V, Townsend RR, Rosas SE. Aortic pulse pressure is associated with carotid IMT in chronic kidney disease: report from Chronic Renal Insufficiency Cohort. Am J Hypertens. 2009 Dec;22(12):1235-41. doi: 10.1038/ajh.2009.156. Epub 2009 Sep 24.
Reference Type
RESULT
Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, O'Connor A, Perumal K, Rahman M, Steigerwalt S, Teal V, Townsend R, Weir M, Wright JT Jr; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010 Mar;55(3):441-51. doi: 10.1053/j.ajkd.2009.09.014. Epub 2009 Dec 5.
Reference Type
RESULT
Joffe M, Hsu CY, Feldman HI, Weir M, Landis JR, Hamm LL; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Variability of creatinine measurements in clinical laboratories: results from the CRIC study. Am J Nephrol. 2010;31(5):426-34. doi: 10.1159/000296250. Epub 2010 Apr 14.
Reference Type
RESULT
Yaffe K, Ackerson L, Kurella Tamura M, Le Blanc P, Kusek JW, Sehgal AR, Cohen D, Anderson C, Appel L, Desalvo K, Ojo A, Seliger S, Robinson N, Makos G, Go AS; Chronic Renal Insufficiency Cohort Investigators. Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc. 2010 Feb;58(2):338-45. doi: 10.1111/j.1532-5415.2009.02670.x. Epub 2010 Jan 26.
Reference Type
RESULT
Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, Lash JP, Chen J, Steigerwalt SP, Flack J, Go AS, Rafey M, Rahman M, Sheridan A, Gadegbeku CA, Robinson NA, Joffe M. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens. 2010 Mar;23(3):282-9. doi: 10.1038/ajh.2009.240. Epub 2009 Dec 17.
Reference Type
RESULT
Gutierrez OM, Anderson C, Isakova T, Scialla J, Negrea L, Anderson AH, Bellovich K, Chen J, Robinson N, Ojo A, Lash J, Feldman HI, Wolf M; CRIC Study Group. Low socioeconomic status associates with higher serum phosphate irrespective of race. J Am Soc Nephrol. 2010 Nov;21(11):1953-60. doi: 10.1681/ASN.2010020221. Epub 2010 Sep 16.
Reference Type
RESULT
Grunwald JE, Alexander J, Maguire M, Whittock R, Parker C, McWilliams K, Lo JC, Townsend R, Gadegbeku CA, Lash JP, Fink JC, Rahman M, Feldman H, Kusek J, Ojo A; CRIC Study Group. Prevalence of ocular fundus pathology in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010 May;5(5):867-73. doi: 10.2215/CJN.08271109. Epub 2010 Mar 18.
Reference Type
RESULT
Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010 Jun;159(6):1102-7. doi: 10.1016/j.ahj.2010.03.027.
Reference Type
RESULT
Townsend RR, Chirinos JA, Parsa A, Weir MA, Sozio SM, Lash JP, Chen J, Steigerwalt SP, Go AS, Hsu CY, Rafey M, Wright JT Jr, Duckworth MJ, Gadegbeku CA, Joffe MP; Chronic Renal Insufficiency Cohort Investigators. Central pulse pressure in chronic kidney disease: a chronic renal insufficiency cohort ancillary study. Hypertension. 2010 Sep;56(3):518-24. doi: 10.1161/HYPERTENSIONAHA.110.153924. Epub 2010 Jul 26.
Reference Type
RESULT
Townsend RR, Anderson AH, Chen J, Gadebegku CA, Feldman HI, Fink JC, Go AS, Joffe M, Nessel LA, Ojo A, Rader DJ, Reilly MP, Teal V, Teff K, Wright JT, Xie D. Metabolic syndrome, components, and cardiovascular disease prevalence in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Nephrol. 2011;33(6):477-84. doi: 10.1159/000327618. Epub 2011 Apr 27.
Reference Type
RESULT
Kurella Tamura M, Xie D, Yaffe K, Cohen DL, Teal V, Kasner SE, Messe SR, Sehgal AR, Kusek J, DeSalvo KB, Cornish-Zirker D, Cohan J, Seliger SL, Chertow GM, Go AS. Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) study. Clin J Am Soc Nephrol. 2011 Feb;6(2):248-56. doi: 10.2215/CJN.02660310. Epub 2010 Oct 7.
Reference Type
RESULT
Hsu CY, Propert K, Xie D, Hamm L, He J, Miller E, Ojo A, Shlipak M, Teal V, Townsend R, Weir M, Wilson J, Feldman H; CRIC Investigators. Measured GFR does not outperform estimated GFR in predicting CKD-related complications. J Am Soc Nephrol. 2011 Oct;22(10):1931-7. doi: 10.1681/ASN.2010101077. Epub 2011 Sep 15.
Reference Type
RESULT
Shlipak MG, Lash JP, Yang W, Teal V, Keane M, Cappola T, Keller C, Jamerson K, Kusek J, Delafontaine P, He J, Miller ER 3rd, Schreiber M, Go AS; CRIC Investigators. Symptoms characteristic of heart failure among CKD patients without diagnosed heart failure. J Card Fail. 2011 Jan;17(1):17-23. doi: 10.1016/j.cardfail.2010.08.009.
Reference Type
RESULT
Isakova T, Anderson CA, Leonard MB, Xie D, Gutierrez OM, Rosen LK, Theurer J, Bellovich K, Steigerwalt SP, Tang I, Anderson AH, Townsend RR, He J, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant. 2011 Apr;26(4):1258-65. doi: 10.1093/ndt/gfr026. Epub 2011 Mar 7.
Reference Type
RESULT
Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, Chen J, He J, Litbarg N, Ojo A, Rahman M, Rosen L, Sozio SM, Steigerwalt S, Strauss L, Joffe MM. Hemodynamic correlates of proteinuria in chronic kidney disease. Clin J Am Soc Nephrol. 2011 Oct;6(10):2403-10. doi: 10.2215/CJN.01670211. Epub 2011 Aug 18.
Reference Type
RESULT
Fischer MJ, Go AS, Lora CM, Ackerson L, Cohan J, Kusek JW, Mercado A, Ojo A, Ricardo AC, Rosen LK, Tao K, Xie D, Feldman HI, Lash JP; CRIC and H-CRIC Study Groups. CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. Am J Kidney Dis. 2011 Aug;58(2):214-27. doi: 10.1053/j.ajkd.2011.05.010. Epub 2011 Jun 25.
Reference Type
RESULT
Budoff MJ, Rader DJ, Reilly MP, Mohler ER 3rd, Lash J, Yang W, Rosen L, Glenn M, Teal V, Feldman HI; CRIC Study Investigators. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2011 Oct;58(4):519-26. doi: 10.1053/j.ajkd.2011.04.024. Epub 2011 Jul 23.
Reference Type
RESULT
Scialla JJ, Leonard MB, Townsend RR, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, Hanish A, Raj D, Rosas SE, Seliger SL, Weir MR, Parekh RS; CRIC Study Group. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011 Nov;6(11):2612-9. doi: 10.2215/CJN.03910411. Epub 2011 Sep 22.
Reference Type
RESULT
Ricardo AC, Lash JP, Fischer MJ, Lora CM, Budoff M, Keane MG, Kusek JW, Martinez M, Nessel L, Stamos T, Ojo A, Rahman M, Soliman EZ, Yang W, Feldman HI, Go AS; CRIC and HCRIC Investigators. Cardiovascular disease among hispanics and non-hispanics in the chronic renal insufficiency cohort (CRIC) study. Clin J Am Soc Nephrol. 2011 Sep;6(9):2121-31. doi: 10.2215/CJN.11341210.
Reference Type
RESULT
Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011 Jun;79(12):1370-8. doi: 10.1038/ki.2011.47. Epub 2011 Mar 9.
Reference Type
RESULT
Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011 Nov;121(11):4393-408. doi: 10.1172/JCI46122. Epub 2011 Oct 10.
Reference Type
RESULT
Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 Jun 15;305(23):2432-9. doi: 10.1001/jama.2011.826.
Reference Type
RESULT
Anderson AH, Yang W, Hsu CY, Joffe MM, Leonard MB, Xie D, Chen J, Greene T, Jaar BG, Kao P, Kusek JW, Landis JR, Lash JP, Townsend RR, Weir MR, Feldman HI; CRIC Study Investigators. Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2012 Aug;60(2):250-61. doi: 10.1053/j.ajkd.2012.04.012. Epub 2012 Jun 2.
Reference Type
RESULT
He J, Reilly M, Yang W, Chen J, Go AS, Lash JP, Rahman M, DeFilippi C, Gadegbeku C, Kanthety R, Tao K, Hamm LL, Ojo A, Townsend R, Budoff M; CRIC Investigators. Risk factors for coronary artery calcium among patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study). Am J Cardiol. 2012 Dec 15;110(12):1735-41. doi: 10.1016/j.amjcard.2012.07.044. Epub 2012 Sep 14.
Reference Type
RESULT
Fischer MJ, Xie D, Jordan N, Kop WJ, Krousel-Wood M, Kurella Tamura M, Kusek JW, Ford V, Rosen LK, Strauss L, Teal VL, Yaffe K, Powe NR, Lash JP; CRIC Study Group Investigators. Factors associated with depressive symptoms and use of antidepressant medications among participants in the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic-CRIC Studies. Am J Kidney Dis. 2012 Jul;60(1):27-38. doi: 10.1053/j.ajkd.2011.12.033. Epub 2012 Apr 11.
Reference Type
RESULT
Chen J, Mohler ER 3rd, Xie D, Shlipak MG, Townsend RR, Appel LJ, Raj DS, Ojo AO, Schreiber MJ, Strauss LF, Zhang X, Wang X, He J, Hamm LL; CRIC Investigators. Risk factors for peripheral arterial disease among patients with chronic kidney disease. Am J Cardiol. 2012 Jul 1;110(1):136-41. doi: 10.1016/j.amjcard.2012.02.061. Epub 2012 Mar 31.
Reference Type
RESULT
Adeseun GA, Xie D, Wang X, Joffe MM, Mohler ER 3rd, Townsend RR, Budoff M, Rosas SE. Carotid plaque, carotid intima-media thickness, and coronary calcification equally discriminate prevalent cardiovascular disease in kidney disease. Am J Nephrol. 2012;36(4):342-7. doi: 10.1159/000342794. Epub 2012 Sep 26.
Reference Type
RESULT
Wahl P, Xie H, Scialla J, Anderson CA, Bellovich K, Brecklin C, Chen J, Feldman H, Gutierrez OM, Lash J, Leonard MB, Negrea L, Rosas SE, Anderson AH, Townsend RR, Wolf M, Isakova T; Chronic Renal Insufficiency Cohort Study Group. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care. 2012 May;35(5):994-1001. doi: 10.2337/dc11-2235. Epub 2012 Mar 23.
Reference Type
RESULT
Lora CM, Ricardo AC, Brecklin CS, Fischer MJ, Rosman RT, Carmona E, Lopez A, Balaram M, Nessel L, Tao KK, Xie D, Kusek JW, Go AS, Lash JP. Recruitment of Hispanics into an observational study of chronic kidney disease: the Hispanic Chronic Renal Insufficiency Cohort Study experience. Contemp Clin Trials. 2012 Nov;33(6):1238-44. doi: 10.1016/j.cct.2012.07.012. Epub 2012 Jul 27.
Reference Type
RESULT
Grunwald JE, Alexander J, Ying GS, Maguire M, Daniel E, Whittock-Martin R, Parker C, McWilliams K, Lo JC, Go A, Townsend R, Gadegbeku CA, Lash JP, Fink JC, Rahman M, Feldman H, Kusek JW, Xie D, Jaar BG; CRIC Study Group. Retinopathy and chronic kidney disease in the Chronic Renal Insufficiency Cohort (CRIC) study. Arch Ophthalmol. 2012 Sep;130(9):1136-44. doi: 10.1001/archophthalmol.2012.1800.
Reference Type
RESULT
Grunwald JE, Ying GS, Maguire M, Pistilli M, Daniel E, Alexander J, Whittock-Martin R, Parker C, Mohler E, Lo JC, Townsend R, Gadegbeku CA, Lash JP, Fink JC, Rahman M, Feldman H, Kusek JW, Xie D, Coleman M, Keane MG; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Association between retinopathy and cardiovascular disease in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC] Study). Am J Cardiol. 2012 Jul 15;110(2):246-53. doi: 10.1016/j.amjcard.2012.03.014. Epub 2012 Apr 18.
Reference Type
RESULT
Scialla JJ, Appel LJ, Wolf M, Yang W, Zhang X, Sozio SM, Miller ER 3rd, Bazzano LA, Cuevas M, Glenn MJ, Lustigova E, Kallem RR, Porter AC, Townsend RR, Weir MR, Anderson CA; Chronic Renal Insufficiency Cohort-CRIC Study Group. Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study. J Ren Nutr. 2012 Jul;22(4):379-388.e1. doi: 10.1053/j.jrn.2012.01.026. Epub 2012 Apr 4.
Reference Type
RESULT
Weir MR, Townsend RR, Fink JC, Teal V, Sozio SM, Anderson CA, Appel LJ, Turban S, Chen J, He J, Litbarg N, Ojo A, Rahman M, Rosen L, Steigerwalt S, Strauss L, Joffe MM. Urinary sodium is a potent correlate of proteinuria: lessons from the chronic renal insufficiency cohort study. Am J Nephrol. 2012;36(5):397-404. doi: 10.1159/000342966. Epub 2012 Oct 12.
Reference Type
RESULT
Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS; CRIC Study Investigators. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012 Dec;7(12):1938-46. doi: 10.2215/CJN.03500412. Epub 2012 Sep 27.
Reference Type
RESULT
Park M, Hsu CY, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, Chen J, He J, Anderson A, Go AS, Shlipak MG; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol. 2012 Oct;23(10):1725-34. doi: 10.1681/ASN.2012020145. Epub 2012 Aug 30.
Reference Type
RESULT
Yaffe K, Ackerson L, Hoang TD, Go AS, Maguire MG, Ying GS, Daniel E, Bazzano LA, Coleman M, Cohen DL, Kusek JW, Ojo A, Seliger S, Xie D, Grunwald JE; CRIC Study Investigators. Retinopathy and cognitive impairment in adults with CKD. Am J Kidney Dis. 2013 Feb;61(2):219-27. doi: 10.1053/j.ajkd.2012.10.006. Epub 2012 Dec 1.
Reference Type
RESULT
Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M; Chronic Renal Insufficiency Cohort. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol. 2012 Jul;7(7):1155-62. doi: 10.2215/CJN.13281211. Epub 2012 May 3.
Reference Type
RESULT
Margolis DJ, Gupta J, Thom SR, Townsend RR, Kanetsky PA, Hoffstad O, Papdopoulos M, Fischer M, Schelling JR, Mitra N. Diabetes, lower extremity amputation, loss of protective sensation, and neuronal nitric oxide synthase associated protein in the chronic renal insufficiency cohort study. Wound Repair Regen. 2013 Jan-Feb;21(1):17-24. doi: 10.1111/j.1524-475X.2012.00866.x. Epub 2012 Dec 10.
Reference Type
RESULT
Ricardo AC, Hacker E, Lora CM, Ackerson L, DeSalvo KB, Go A, Kusek JW, Nessel L, Ojo A, Townsend RR, Xie D, Ferrans CE, Lash JP; CRIC Investigators. Validation of the Kidney Disease Quality of Life Short Form 36 (KDQOL-36) US Spanish and English versions in a cohort of Hispanics with chronic kidney disease. Ethn Dis. 2013 Spring;23(2):202-9.
Reference Type
RESULT
Bansal N, Keane M, Delafontaine P, Dries D, Foster E, Gadegbeku CA, Go AS, Hamm LL, Kusek JW, Ojo AO, Rahman M, Tao K, Wright JT, Xie D, Hsu CY; CRIC Study Investigators. A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study. Clin J Am Soc Nephrol. 2013 Mar;8(3):355-62. doi: 10.2215/CJN.06020612. Epub 2013 Feb 14.
Reference Type
RESULT
Ferguson JF, Matthews GJ, Townsend RR, Raj DS, Kanetsky PA, Budoff M, Fischer MJ, Rosas SE, Kanthety R, Rahman M, Master SR, Qasim A, Li M, Mehta NN, Shen H, Mitchell BD, O'Connell JR, Shuldiner AR, Ho WK, Young R, Rasheed A, Danesh J, He J, Kusek JW, Ojo AO, Flack J, Go AS, Gadegbeku CA, Wright JT Jr, Saleheen D, Feldman HI, Rader DJ, Foulkes AS, Reilly MP; CRIC Study Principal Investigators. Candidate gene association study of coronary artery calcification in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort). J Am Coll Cardiol. 2013 Aug 27;62(9):789-98. doi: 10.1016/j.jacc.2013.01.103. Epub 2013 May 30.
Reference Type
RESULT
Mishra RK, Li Y, DeFilippi C, Fischer MJ, Yang W, Keane M, Chen J, He J, Kallem R, Horwitz EJ, Rafey M, Raj DS, Go AS, Shlipak MG; CRIC Study Investigators. Association of cardiac troponin T with left ventricular structure and function in CKD. Am J Kidney Dis. 2013 May;61(5):701-9. doi: 10.1053/j.ajkd.2012.11.034. Epub 2013 Jan 4.
Reference Type
RESULT
Mishra RK, Li Y, Ricardo AC, Yang W, Keane M, Cuevas M, Christenson R, deFilippi C, Chen J, He J, Kallem RR, Raj DS, Schelling JR, Wright J, Go AS, Shlipak MG; Chronic Renal Insufficiency Cohort Investigators. Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC]). Am J Cardiol. 2013 Feb 1;111(3):432-8. doi: 10.1016/j.amjcard.2012.10.019. Epub 2012 Nov 22.
Reference Type
RESULT
Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M; Chronic Renal Insufficiency Cohort Study Investigators. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 2013 Jun;83(6):1159-68. doi: 10.1038/ki.2013.3. Epub 2013 Feb 6.
Reference Type
RESULT
Liu KD, Yang W, Anderson AH, Feldman HI, Demirjian S, Hamano T, He J, Lash J, Lustigova E, Rosas SE, Simonson MS, Tao K, Hsu CY; Chronic Renal Insufficiency Cohort (CRIC) study investigators. Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int. 2013 May;83(5):909-14. doi: 10.1038/ki.2012.458. Epub 2013 Jan 23.
Reference Type
RESULT
Dobre M, Yang W, Chen J, Drawz P, Hamm LL, Horwitz E, Hostetter T, Jaar B, Lora CM, Nessel L, Ojo A, Scialla J, Steigerwalt S, Teal V, Wolf M, Rahman M; CRIC Investigators. Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2013 Oct;62(4):670-8. doi: 10.1053/j.ajkd.2013.01.017. Epub 2013 Mar 13.
Reference Type
RESULT
Ky B, Shults J, Keane MG, Sutton MS, Wolf M, Feldman HI, Reese PP, Anderson CA, Townsend RR, Deo R, Lo J, Gadegbeku C, Carlow D, Sulik MJ, Leonard MB; CRIC Study Investigators. FGF23 modifies the relationship between vitamin D and cardiac remodeling. Circ Heart Fail. 2013 Jul;6(4):817-24. doi: 10.1161/CIRCHEARTFAILURE.112.000105. Epub 2013 Jun 7.
Reference Type
RESULT
Park CH, Kim HW, Park JT, Chang TI, Yoo TH, Oh KH, Anderson AH, Yang W, Cohen JB, Rahman M, Kang SW, Han SH; on the behalf of CRIC Study and KNOW-CKD Investigators. BP and Kidney Disease Progression in Advanced CKD: Findings from the Chronic Renal Insufficiency Cohort and KoreaN Cohort Study for Outcome in Patients with CKD Studies. Clin J Am Soc Nephrol. 2025 Jun 6;20(9):1179-1189. doi: 10.2215/CJN.0000000760.
Reference Type
DERIVED
Yuan Y, Liu M, Zhang S, Lin Y, Huang Y, Zhou H, Xu X, Zhuang X, Liao X. Effect of blood pressure index on clinical outcomes in patients with heart failure and chronic kidney disease. ESC Heart Fail. 2023 Dec;10(6):3330-3339. doi: 10.1002/ehf2.14437. Epub 2023 Sep 4.
Reference Type
DERIVED
Anderson AH, Xie D, Wang X, Baudier RL, Orlandi P, Appel LJ, Dember LM, He J, Kusek JW, Lash JP, Navaneethan SD, Ojo A, Rahman M, Roy J, Scialla JJ, Sondheimer JH, Steigerwalt SP, Wilson FP, Wolf M, Feldman HI; CRIC Study Investigators. Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2021 Jan;77(1):56-73.e1. doi: 10.1053/j.ajkd.2020.07.011. Epub 2020 Aug 28.
Reference Type
DERIVED
Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, Charleston J, He J, Kallem R, Lash JP, Miller ER 3rd, Rahman M, Steigerwalt S, Weir M, Wright JT Jr, Feldman HI; Chronic Renal Insufficiency Cohort Study Investigators. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann Intern Med. 2015 Feb 17;162(4):258-65. doi: 10.7326/M14-0488.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
http://www.cristudy.org
The CRIC Study website has a section of general information about the study and kidney disease for members of the general public who may be interested. It includes a brief description of the study and the 13 participating clinical centers.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DK60990
Identifier Type: -
Identifier Source: org_study_id